Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Tandem Diabetes Care, Inc. is a U.S.-based medical device company focused on the design, development, and commercialization of insulin delivery systems for people with diabetes, primarily insulin-dependent Type 1 diabetes and insulin-requiring Type 2 diabetes. The company operates within the medical devices and diabetes care technology industries and generates revenue primarily through the sale of insulin pumps, pump-related consumables, and integrated diabetes management software.
Tandem’s core products include its t:slim X2 insulin pump platform and associated infusion sets and cartridges, as well as its proprietary Control-IQ automated insulin delivery algorithm, which integrates with continuous glucose monitoring (CGM) systems. The company is recognized for its touchscreen-based pump design and software-updatable platform, which allows users to receive feature enhancements without replacing hardware. Founded in 2006, Tandem experienced early financial challenges, followed by a strategic turnaround driven by technological differentiation, regulatory approvals, and growing adoption of automated insulin delivery systems.
Business Operations
Tandem operates primarily through a single reportable operating segment focused on insulin pump systems and related supplies, with revenue generated from both initial device sales and recurring consumable purchases. The company’s products include the t:slim X2 insulin pump, Mobi insulin pump, infusion sets, cartridges, and cloud-based data management tools such as t:connect. A significant portion of revenue is recurring, derived from ongoing patient use of disposable supplies.
Operations are concentrated in the United States, which represents the majority of revenue, with international sales supported through direct operations and distribution partners. Tandem maintains manufacturing, quality, and distribution capabilities, while key technologies include proprietary pump hardware, embedded software, and algorithm-driven insulin automation. The company has strategic technology integrations with CGM providers, most notably Dexcom, but does not own CGM manufacturing assets.
Strategic Position & Investments
Tandem’s strategic direction centers on expanding adoption of automated insulin delivery, improving form factor and usability, and broadening its addressable patient population. Key growth initiatives include the launch and scaling of the Tandem Mobi system, continued enhancements to Control-IQ technology, and pipeline development of next-generation insulin delivery platforms with smaller, more discreet designs.
The company invests heavily in research and development to maintain regulatory leadership and competitive differentiation against larger diabetes device manufacturers. Tandem does not operate as a diversified holding company and has limited acquisition activity; instead, it prioritizes internal development and selective technology collaborations. Emerging focus areas include expanded indications for Type 2 diabetes, software-driven therapy personalization, and increased international penetration.
Geographic Footprint
Tandem is headquartered in North America, with its corporate headquarters located in the United States. The company’s primary commercial market is the U.S., which accounts for the majority of installed base, revenue, and clinical adoption. Domestic operations include sales, customer support, training, and logistics infrastructure.
Internationally, Tandem has expanded its presence across Europe, Australia, and select additional markets through a combination of direct subsidiaries and third-party distributors. While international revenue remains a smaller proportion of total sales compared to the U.S., it represents a strategic growth area supported by regulatory approvals and increasing global demand for automated insulin delivery technologies.
Leadership & Governance
Tandem was founded by Kim D. Blickenstaff, who played a central role in establishing the company’s early vision and product strategy. The current leadership team emphasizes patient-centric design, software-enabled innovation, and disciplined operational execution to drive sustainable growth in a competitive medical technology market.
Key executives include:
- John F. Sheridan – President and Chief Executive Officer
- Leanne Azevedo – Executive Vice President and Chief Financial Officer
- John L. Foster – Executive Vice President and Chief Operating Officer
- Nick Jonas – Executive Vice President and Chief Legal Officer
- Diego Verdugo – Executive Vice President and Chief Marketing Officer
The company is governed by a Board of Directors with experience across medical devices, healthcare, and public company leadership, and management has articulated a strategic vision focused on improving clinical outcomes, expanding access, and leveraging software as a long-term competitive advantage.